全文获取类型
收费全文 | 224263篇 |
免费 | 12460篇 |
国内免费 | 6393篇 |
专业分类
耳鼻咽喉 | 2768篇 |
儿科学 | 8338篇 |
妇产科学 | 2995篇 |
基础医学 | 16524篇 |
口腔科学 | 4219篇 |
临床医学 | 27213篇 |
内科学 | 39845篇 |
皮肤病学 | 3026篇 |
神经病学 | 10886篇 |
特种医学 | 14910篇 |
外国民族医学 | 23篇 |
外科学 | 33402篇 |
综合类 | 20144篇 |
现状与发展 | 25篇 |
预防医学 | 14687篇 |
眼科学 | 4409篇 |
药学 | 23720篇 |
86篇 | |
中国医学 | 4518篇 |
肿瘤学 | 11378篇 |
出版年
2023年 | 1979篇 |
2022年 | 3787篇 |
2021年 | 9116篇 |
2020年 | 5344篇 |
2019年 | 11332篇 |
2018年 | 5947篇 |
2017年 | 5080篇 |
2016年 | 7039篇 |
2015年 | 9898篇 |
2014年 | 17991篇 |
2013年 | 15600篇 |
2012年 | 19055篇 |
2011年 | 15873篇 |
2010年 | 14619篇 |
2009年 | 14301篇 |
2008年 | 12782篇 |
2007年 | 12923篇 |
2006年 | 10911篇 |
2005年 | 7233篇 |
2004年 | 3674篇 |
2003年 | 3216篇 |
2002年 | 2624篇 |
2001年 | 2076篇 |
2000年 | 1826篇 |
1999年 | 1137篇 |
1998年 | 1525篇 |
1997年 | 1367篇 |
1996年 | 1147篇 |
1995年 | 1199篇 |
1994年 | 1156篇 |
1993年 | 888篇 |
1992年 | 1107篇 |
1991年 | 988篇 |
1990年 | 1034篇 |
1989年 | 1009篇 |
1988年 | 931篇 |
1987年 | 826篇 |
1986年 | 674篇 |
1985年 | 1628篇 |
1984年 | 1801篇 |
1983年 | 1312篇 |
1982年 | 1380篇 |
1981年 | 1376篇 |
1980年 | 1202篇 |
1979年 | 1024篇 |
1978年 | 809篇 |
1977年 | 797篇 |
1976年 | 692篇 |
1974年 | 460篇 |
1973年 | 447篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
Guillermo Garcia-Manero Antonio Almeida Pierre Fenaux Norbert Gattermann Aristoteles Giagounidis Stuart L. Goldberg Keiya Ozawa Jerry Weaver Valeria Santini 《Clinical Lymphoma, Myeloma & Leukemia》2019,19(4):213-219.e4
BackgroundIn the phase III MDS-005 study of patients with lower-risk, non-del(5q) myelodysplastic syndromes, lenalidomide was associated with a higher rate of ≥ 8 weeks red blood cell transfusion independence (RBC-TI) compared with placebo, but also with a higher risk of hematologic adverse events (AEs).Patients and MethodsThis analysis evaluated the ratio of clinical benefit-risk in patients treated with lenalidomide or placebo, and assessed the effect of lenalidomide dose reductions on response. Clinical benefit was a composite endpoint defined as RBC-TI, transfusion reduction ≥ 4 units packed red blood cells, hemoglobin increase ≥ 1.5 g/dL, or cytogenetic response.ResultsThe rate of clinical benefit was higher with lenalidomide than with placebo (31.9% vs. 3.8%). The ratio of response (RBC-TI and clinical benefit) to risk (hematologic AEs) favored lenalidomide over placebo. Patients who underwent ≥ 1 lenalidomide dose reduction had a longer duration of treatment, received a higher cumulative dose, and were more likely to experience clinical benefit versus patients without dose reductions.ConclusionDespite the occurrence of hematologic AEs, the overall benefit-risk profile supported lenalidomide treatment. Appropriate management of hematologic AEs by dose reductions may help patients with myelodysplastic syndromes to remain on treatment and achieve clinical benefit. 相似文献
92.
2017年1月与9月,《WHO头颈肿瘤分类》(第4版)与《WHO造血淋巴组织肿瘤分类》(修订第4版)两本蓝皮书相继面世,笔者也有幸受邀参与了《WHO头颈肿瘤分类》(第4版)一书中淋巴造血组织肿瘤有关章节的编写工作,分别对这两个新分类中关于头颈区黏膜淋巴组织增生性疾病的内容更新、头颈区黏膜淋巴瘤的诊断方法以及该区域常见淋巴瘤类型的诊断与鉴别诊断要点作一简介。 相似文献
93.
94.
95.
《药学学报(英文版)》2020,10(5):799-811
Overexpression of adenosine triphosphate (ATP)-binding cassette subfamily G member 2 (ABCG2) in cancer cells is known to cause multidrug resistance (MDR), which severely limits the clinical efficacy of chemotherapy. Currently, there is no FDA-approved MDR modulator for clinical use. In this study, rociletinib (CO-1686), a mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was found to significantly improve the efficacy of ABCG2 substrate chemotherapeutic agents in the transporter-overexpressing cancer cells in vitro and in MDR tumor xenografts in nude mice, without incurring additional toxicity. Mechanistic studies revealed that in ABCG2-overexpressing cancer cells, rociletinib inhibited ABCG2-mediated drug efflux and increased intracellular accumulation of ABCG2 probe substrates. Moreover, rociletinib, inhibited the ATPase activity, and competed with [125I] iodoarylazidoprazosin (IAAP) photolabeling of ABCG2. However, ABCG2 expression at mRNA and protein levels was not altered in the ABCG2-overexpressing cells after treatment with rociletinib. In addition, rociletinib did not inhibit EGFR downstream signaling and phosphorylation of protein kinase B (AKT) and extracellular signal-regulated kinase (ERK). Our results collectively showed that rociletinib reversed ABCG2-mediated MDR by inhibiting ABCG2 efflux function, thus increasing the cellular accumulation of the transporter substrate anticancer drugs. The findings advocated the combination use of rociletinib and other chemotherapeutic drugs in cancer patients with ABCG2-overexpressing MDR tumors. 相似文献
96.
目的 分析2型糖尿病(T2DM)患者视网膜病变(DR)患病率及其相关因素。方法 对3 404例2型糖尿病住院患者进行回顾性研究,根据眼科会诊结果,将患者分为3组,其中非DR组(A组/NDR组)2 562例,DR非增殖期组(B组/NPDR组)716例,DR增殖期组(C组/PDR组)126例。得出DR的患病率,比较3组患者之间临床资料及临床指标的异同,及其与DR的相关性。结果 2型糖尿病患者DR患病率达24.7%,与甘油三酯(OR=1.110,P=0.000)、糖化血红蛋白(HbA1c)(OR=1.087,P=0.000)、血尿酸(OR=1.003,P=0.000)、病程(OR=1.002,P=0.000)相关。结论 2型糖尿病患者DR患病率为24.7%,高血脂、高血糖、高尿酸血症、病程长为DR的独立危险因素。早期发现糖尿病、早期治疗糖尿病、积极控制血糖血脂血尿酸,对于减少DR的发生及延缓DR的发展意义重大。 相似文献
97.
目的:研究影像学在诊断应力性骨折中的应用。方法:选取2013年1月—2017年12月南京医科大学第一附属医院收治的82例保有影像学资料并诊断明确的应力性骨折患者作为研究对象,对患者影像学资料进行回顾性分析,并比较分析X线、CT、MRI对应力性骨折的诊断准确率及漏诊的原因。结果:82例应力性骨折患者的男女比例为1∶1.9,平均年龄为49.77岁;病变多累及下肢骨及中轴骨,胫骨为最常见累及部位;X线、CT、MRI的诊断准确率依次升高,X线、CT的初诊漏诊与MRI分级之间的关系无统计学意义;X线及CT图像中骨膜反应易被漏诊。结论:应力性骨折的影像学诊断应结合临床病史及好发部位,早期诊断应力性骨折首选MRI,注重X线及CT中骨膜反应及软组织情况以减少漏诊率。 相似文献
98.
99.
Chu-Chih Chen Yin-Han Wang Wei J. Chen Chao A. Hsiung Yue-Liang Leon Guo Shu-Li Julie Wang 《International journal of hygiene and environmental health》2019,222(6):971-980
IntroductionPrenatal exposure to di(2-ethylhexyl) phthalate (DEHP) has been reported to be associated with adverse effects on neurodevelopment that yield behavior syndromes in young children with an estimated median exposure lower than the currently recommended tolerable daily intake (TDI) and reference dose (RfD).ObjectivesOur aim was to derive the benchmark dose for prenatal exposure to DEHP for the neurodevelopmental health in children.MethodsA total of 122 mother-child pairs from the Taiwan Maternal and Infant Cohort Study were analyzed for the dose-response relationship between maternal exposure to DEHP and children's behavioral syndromes evaluated at 8 years (n = 122, 2009), 11 years (n = 96, 2012), and 14 years (n = 78, 2015) of age. We employed a multivariate regression model to assess the statistical associations between the estimated maternal average daily intake of DEHP and child's individual CBCL scores for boys and girls at each separate age, followed by a mixed model for all the children across three ages accounting for individual variations. We then employed structural equation models by combining the children's specific behavioral problem scores at different ages and obtained a simulated overall latent score in relation to maternal exposure. Based on the established dose-response relationship, we derived the benchmark dose (BMD) and the lower limit (BMDL).ResultsAssociations of maternal DEHP exposure (median 4.54) with the Child Behavior Checklist (CBCL) scores were all significant, except for somatic complaints, adjusting for child's age, gender, IQ, and family income. The BMDL, given a benchmark response of 0.10 (0.05) and a background response of 0.05, was 6.01 (2.16) for an integrated CBCL score.ConclusionsThe current TDI (RfD) of 50 (20) for DEHP might not protect pregnant women for their children from behavioral problems. There remains the lack of comparable toxicological data. Further investigations are needed. 相似文献
100.